fluticasone

(redirected from Veramyst)
Also found in: Dictionary.

fluticasone

 [floo-tik´ah-sōn″]
a steroid antiinflammatory agent, used as the propionate salt topically in treatment of itching or inflammation, intranasally for allergic rhinitis and other inflammatory nasal conditions, and nasal polyps, and by inhalation in treatment of asthma.

fluticasone

/flu·tic·a·sone/ (floo-tik´ah-sōn″) a synthetic corticosteroid used as the propionate salt to treat inflammation in certain dermatoses, allergic rhinitis and other inflammatory nasal conditions, nasal polyps, and asthma.

fluticasone

[floo͡tik′äsōn′]
a steroid antiinflammatory agent, used topically as the propionate salt in treatment of itching or inflammation, intranasally in the treatment of allergic rhinitis and other inflammatory nasal conditions and of nasal polyps, and by inhalation in treatment of asthma.

fluticasone

A CORTICOSTEROID drug used as an inhalant to treat ASTHMA and hay fever. Extensive studies have shown that fluticasone is safe and effective and, in the recommended dosage, does not affect growth in childhood. Brand names are Flixonase (nasal spray), Flixotide (inhaler) and, for external use only, Cutivate. With SALMETEROL it is marketed as Seretide.
References in periodicals archive ?
The FDA approved once-daffy Veramyst (fluticasone furoate) nasal spray to treat symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.
Comment: Phase III studies of 1,112 children aged 2-11 years with seasonal or perennial allergies demonstrated the efficacy of Veramyst.
Five clinical trials with a total of 1,829 patients aged 12 years and older indicated that Veramyst was more effective than placebo in improvement of overall nasal symptoms.
For once-a-day treatment, consider Veramyst nasal spray; to save money, consider nonprescription Zyrtec-D.
LOS ANGELES -- Under the category for "Dental instruments, equipment, and supplies," please note removal of the product Veramyst and Avamys (Fluticasone Furoate) nasal spray delivery device (GlaxoSmithKline R&D).
CHICAGO -- Celsis International plc today announces that GlaxoSmithKline's New Drug Application (NDA) for Veramyst nasal spray, is the first approval of an NDA that references Celsis' Rapid Microbiological Method (RMM) as part of a regulatory submission.
The FDA's approval of Veramyst builds on acceptance of the Celsis Rapid Detection System as a microbiological in-process and end-product release testing method for pharmaceutical and biopharmaceutical products by other regulatory agencies around the world.
We are pleased that GlaxoSmithKline received FDA approval for Veramyst, where the Celsis system is its primary microbial screening method for end-product release," said Jay LeCoque, Chief Executive Officer of Celsis.